乳腺癌环磷酰胺治疗的药物基因组学研究进展

中国临床药理学与治疗学 ›› 2014, Vol. 19 ›› Issue (10): 1196-1200.

• 综述与讲座 • 上一篇

乳腺癌环磷酰胺治疗的药物基因组学研究进展

黄征宇¹, 刘芳群¹, 高利臣¹, 汪砥¹, 贺毅憬², 陈小平³

¹ 长沙市中心医院药学部,肿瘤研究所,长沙 410004,湖南;
² 中南大学湘雅医院皮肤科, 长沙 410008,湖南;
³ 中南大学临床药理研究所,长沙 410078,湖南

收稿日期:2014-03-25 修回日期:2014-09-05 出版日期:2014-10-26 发布日期:2014-10-29
通讯作者: 高利臣,男,博士,讲师(主管药师),研究方向:临床药理学与药物基因组学研究。Tel: 0731-85667872 E-mail: gonedog1224@hotmail.com
作者简介:黄征宇, 男, 本科, 副主任医师, 研究方向:心血管内科疾病诊断与药物治疗研究。 Tel: 0731-85668106 E-mail: 18274979797@126.com。刘芳群,共同第一作者,女,硕士,主任药师,研究方向:医院药事管理与临床药学研究。Tel: 0731-85668040 E-mail: lfq811@qq.com
基金资助:
湖南省科技厅项目(2014SS2033); 长沙市科技局2013年度指导性科技计划项目(K13ZD075-33)

Advances in pharmacogenomics of cyclophosphamide in the breast cancer therapy

HUANG Zheng-yu¹, LIU Fang-qun¹, GAO Li-chen¹, WANG Di¹, HE Yi-jing², CHENG Xiao-ping³

¹ Department of Pharmacy, Cancer Institute, Changsha Central Hospital, Changsha 410078, Hunan, China;
² Department of Dermatology, Xiang Ya Hospital, Central South University, Changsha 410008, Hunan, China;
³ Institute of Clinical Pharmacology, Central South University, Changsha 410078, Hunan, China

Received:2014-03-25 Revised:2014-09-05 Online:2014-10-26 Published:2014-10-29

摘要/Abstract

摘要： 环磷酰胺作为乳腺癌最主要的化疗用药,在乳腺癌治疗中具有显著的药动学、不良反应和药效个体差异,给药剂量难以控制,并可导致严重的血液系统、消化系统不良反应。研究显示环磷酰胺体内代谢酶的功能性遗传变异决定了其体内处置、不良反应及临床疗效。本文综述了近年来环磷酰胺代谢酶功能性遗传变异,在乳腺癌临床治疗中药物基因组学研究的新进展。

关键词: 环磷酰胺, 乳腺癌, 药物基因组学, 药物代谢酶, 化疗治疗

Abstract: Cyclophosphamide (CPA) is widely used in the breast cancer therapy. However, significant individual differences of CPA in the pharmacokinetics, adverse reactions and efficacy have been observed, which made it difficult to decide a suitable dose in clinic. Previous clinical investigation indicated that functional genetic variation of metabolic enzymes of CPA played important roles in the metabolisms, adverse reactions and clinical efficacy of CPA. This paper reviews the recent clinical research advances about pharmacogenomics of CPA in the breast cancer therapy.

Key words: cyclophosphamide, breast cancer, pharmacogenomics, drug metabolized enzymes, chemotherapy

中图分类号:

R968
R969.1

黄征宇, 刘芳群, 高利臣, 汪砥, 贺毅憬, 陈小平. 乳腺癌环磷酰胺治疗的药物基因组学研究进展[J]. 中国临床药理学与治疗学, 2014, 19(10): 1196-1200.

HUANG Zheng-yu, LIU Fang-qun, GAO Li-chen, WANG Di, HE Yi-jing, CHENG Xiao-ping. Advances in pharmacogenomics of cyclophosphamide in the breast cancer therapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(10): 1196-1200.

参考文献 28

[1]	DeSantis C, Siegel R, Bandi P, et al. Breast cancer statistics[J]. CA Cancer J Clin, 2011, 61: 409-418.
[2]	Lyman GH, Dale DC, Tomita D, et al.A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting[J]. Breast Cancer Res Treat, 2013, 139(3): 863-872.
[3]	Pinto N, Ludeman SM, Dolan ME.Drug focus: pharmacogenetic studies related to cyclophosphamide-based therapy[J]. Pharmacogenomics, 2009, 10(12): 1893-1903.
[4]	Bray J, Sludden J, Griffin MJ, et al.Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide[J]. Br J Cancer, 2010, 102(6): 1003-1009.
[5]	Su HI, Sammel MD, Velders L, et al.Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors[J]. Fertil Steril, 2010, 94(2): 645-654.
[6]	Timm R, Kaiser R, Lotsch J, et al.Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19[J]. Pharmacogenomics J, 2005, 5(6): 365-373.
[7]	Wang D, Wang HB.Oxazaphosphorine bioactivation and detoxification: the role of xenobiotic receptors[J]. Acta Pharm Sin B, 2012, 2(2): 1-21.
[8]	Gor PP, Su HI, Gray RJ, et al.Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study[J]. Breast Cancer Res, 2010, 12(3): R26.
[9]	Huang Z, Roy P, Waxman DJ.Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide[J]. Biochem Pharmacol, 2000, 59(8): 961-972.
[10]	Roy P, Yu LJ, Crespi CL, et al.Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles[J]. Drug Metab Dispos, 1999, 27(6): 655-666.
[11]	Zhang H, Sridar C, Kenaan C, et al.Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex[J]. J Pharmacol Exp Ther, 2011, 338(3): 803-809.
[12]	Saitoh A, Sarles E, Capparelli E, et al.CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children[J]. AIDS, 2007, 21(16): 2191-2199.
[13]	Nyakutira C, Roshammar D, Chigutsa E, et al.High prevalence of the CYP2B6 516G.T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe[J]. Eur J Clin Pharmacol, 2008, 64(4): 357-365.
[14]	Zanger UM, Klein K.Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance[J]. Front Genet, 2013, 3(4): 1-12.
[15]	李莉华, 周希科, 何杰, 等. CYP2B6Q172H和K262R基因多态性对乳腺癌患者环磷酰胺化疗预后的影响[J]. 肿瘤防治研究, 2010, 37(12): 1387-1390.
[16]	陈江华, 赵建华, 唐金海, 等. 环磷酰胺代谢酶基因多态性与乳腺癌化疗反应相关性的探讨[J]. 中华肿瘤防治杂志, 2012, 19(10): 726-730.
[17]	王连生. 细胞色素P450氧化酶的遗传药理学[M]//周宏灏, 张伟主编. 遗传药理学. 2版. 北京:科学出版社, 2013: 110-111.
[18]	李清,郭栋. Ⅱ相药物代谢酶的遗传药理学[M]//周宏灏, 张伟主编. 遗传药理学. 2版. 北京:科学出版社, 2013: 146-150.
[19]	Ji MH, Tang JH, Zhao JH, et al.Polymorphisms in genes involved in drug detoxification and clinical outcomes of anthracycline-based neoadjuvant chemotherapy in Chinese Han breast cancer patients[J]. Cancer Bio Ther, 2012, 13(5): 264-271.
[20]	Yao S, Barlow WE, Albain KS, et al.Gene polymorphisms in cyclophosphamide metabolism pathway, treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer[J]. Clin Cancer Res, 2010, 16(24): 6169-6176.
[21]	Sweeney C, McClure Y, Fares MY, et al. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism[J]. Clin Cancer Res, 2000, 60: 5621-5624.
[22]	Zhang BL, Sun T, Zhang BN, et al.Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer[J]. Chin Med J, 2011,124(2): 199-204.
[23]	Yang G, Shu XO, Ruan ZX, et al.Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma[J]. Cancer, 2005, 103(1): 52-58.
[24]	Sweeney C, Ambrosone CB, Joseph LJ, et al.Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment[J]. Int J Cancer, 2003, 103(6): 810-814.
[25]	Ekhart C, Rodenhuis S, Smits PHM, et al.Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin[J]. Pharmacogenet Genomics, 2008, 18(11): 1009-1015.
[26]	Kim KP, Ahn JH, Kim SB, et al.Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy[J]. Cancer Chemother Pharmacol, 2012, 69(5): 1221-1227.
[27]	Low SK, Kiyotani K, Mushiroda T, et al.Association study of genetic polymorphism in ABCC4with cyclophosphamide-induced adverse drug reactions in breast cancer patients[J]. J Hum Genet, 2009, 54(10): 564-571.
[28]	孟祥光, 倪文琼, 王超, 等. 银屑病全身治疗的遗传药理学进展[J]. 中国临床药理学与治疗学, 2012, 17(11): 1307-1313.

乳腺癌环磷酰胺治疗的药物基因组学研究进展

Advances in pharmacogenomics of cyclophosphamide in the breast cancer therapy

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献 28

相关文章 15

编辑推荐

Metrics

本文评价

[1]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[2]	张胡云龙, 朱秀之, 金希, 邵志敏. 腔面型乳腺癌内分泌治疗耐药的机制与治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 854-865.
[3]	付晓玉, 孔德光, 李娟娟. 三阳性乳腺癌的治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 866-875.
[4]	罗师萍, 张捷, 俞育帅, 宋传贵. HER2阳性乳腺癌的靶向治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 876-886.
[5]	向奕玫, 张宁宁, 黄雨昕, 曾晓华. HER2阳性乳腺癌疗效相关生物标志物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 887-897.
[6]	陈柯羽, 黄圆, 王晓稼, 郑亚兵. 抗体偶联药物在乳腺癌中的临床应用与研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 898-909.
[7]	李梦茜, 张克兢, 夏凡. 乳腺癌疫苗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 918-925.
[8]	李坤, 李璐璐, 李楠楠, 胡卫红, 周建超. 成人肾移植术后血糖控制和CYP3A5基因多态性对他克莫司谷浓度的影响[J]. 中国临床药理学与治疗学, 2023, 28(7): 767-774.
[9]	王智, 周鑫, 何雪茹, 付裕豪, 荀雪姣, 李颖, 董占军. 哌柏西利治疗乳腺癌的临床研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 205-213.
[10]	王秀, 季麒麟, 裴文俊, 曾颖. 3-溴丙酮酸-胆固醇酯增强乳腺癌细胞对他莫昔芬敏感性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1093-1100.
[11]	武帅, 杨君, 郑云. 乳腺癌中具有双重功能的miRNA[J]. 中国临床药理学与治疗学, 2022, 27(7): 814-821.
[12]	施经斌, 熊阳. 肿瘤微环境与乳腺癌细胞互作导致肿瘤转移的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(5): 562-574.
[13]	董伟, 黄小英, 谢冰斌, 汤喜兰, 李洪铭, 邱雨美, 赵国巍, 梁新丽. 氧化前胡素对乳腺癌MCF-7/DOX细胞多柔比星耐药的抑制作用[J]. 中国临床药理学与治疗学, 2022, 27(3): 260-266.
[14]	孙媛媛, 邓锟红, 王思懿, 况赟, 邹婵, 郭成贤, 何庆南, 刘和林, 阳国平. 个体化用药基因电子身份应用程序的设计与实现[J]. 中国临床药理学与治疗学, 2022, 27(3): 274-280.
[15]	周晗, 刘晓东. 生理药代动力学模型在创新药物评价中应用及其若干问题的思考[J]. 中国临床药理学与治疗学, 2021, 26(8): 889-913.